This invention relates to potent potassium channel blocker compounds of
Formula I or a formulation thereof for the treatment of glaucoma and
other conditions which leads to elevated intraocular pressure in the eye
of a patient. This invention also relates to the use of such compounds to
provide a neuroprotective effect to the eye of mammalian species,
particularly humans.